AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center

by Barry101 | Jan 17, 2023 | Press Release, Uncategorized

Research collaboration will evaluate the potential of AIM’s Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi (durvalumab) for the treatment of pancreatic cancerOCALA, Fla., Jan. 17, 2023 — AIM ImmunoTech Inc. (NYSE American:...

AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention

by Barry101 | Jan 9, 2023 | Press Release, Uncategorized

OCALA, Fla., Jan. 09, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and...

AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’

by Barry101 | Jan 5, 2023 | Press Release, Uncategorized

Live video webcast on Wednesday, January 18th at 11:00 AM ETOCALA, Fla., Jan. 05, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics...

AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer

by Barry101 | Dec 12, 2022 | Press Release, Uncategorized

Accomplished scientist with a diverse range of skills from general wet lab technique to company-wide operations managementOCALA, Fla., Dec. 12, 2022 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma...

AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects

by Barry101 | Dec 8, 2022 | Press Release, Uncategorized

Intranasal administration of Ampligen demonstrated to be well-tolerated Based on data generated to date, Ampligen could have potential as a prophylactic or early treatment against respiratory viral infections Data presented in poster presentation at the British...

AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022

by Barry101 | Dec 2, 2022 | Press Release, Uncategorized

OCALA, Fla., Dec. 02, 2022 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...